A Comparative Study of Olopatadine Hydrochloride Ophthalmic Solution 0.2% QD vs Olopatadine Hydrochloride Ophthalmic Solution 0.1% BID in the Treatment of Allergic Conjunctivitis in Chinese Subjects

Trial Profile

A Comparative Study of Olopatadine Hydrochloride Ophthalmic Solution 0.2% QD vs Olopatadine Hydrochloride Ophthalmic Solution 0.1% BID in the Treatment of Allergic Conjunctivitis in Chinese Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Olopatadine (Primary)
  • Indications Allergic conjunctivitis
  • Focus Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 28 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016, as reported by ClinicalTrials.gov record.
    • 23 Sep 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2016, as reported by ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top